AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
- A New Miniaturized PCR Instrument With SuperConvection(TM) - At One Sixth the Price of QuanTyper(TM) Without Loss of Performance - Next Generation of PCR Expected to Rapidly Penetrate the Market
UPPSALA,
AmpXpress(TM) will be presented tomorrow at the BIOTECHNICA show in
More information about AmpXpress(TM) is found at http://www.alphahelix.com. The product development has cost approximately 500 KSEK (gross). AlphaHelix has also been granted 250 KSEK by the Swedish Agency for Economic and Regional Growth. A first series of ten instruments has been initiated and patent applications have been submitted.
Technology assessment of SuperConvection and QuanTyper(TM) proceeds at the American biotechnology company and is not affected by the launch of AmpXpress(TM). Results from the evaluation are expected early November, at the earliest.
AlphaHelix Molecular Diagnostics AB (publ) develops instruments for rapid DNA analysis. The company's patented technology enables identification of virus and bacteria faster and with greater sensitivity than other technology available on the market. The AlphaHelix share is traded at AktieTorget http://www.aktietorget.se, which is a multilateral trading facility for small caps under the supervision of the Swedish Financial Supervisory Authority.
For further information: Lars Edvinsson, CEO, phone, +46-768-302-304; or Per Ersson, CFO, phone +46-708-66-24-45
Share this article